Randomized phase II study of docetaxel + bevacizumab or pemetrexed + bevacizumab for elderly non-squamous non-small-cell lung cancer. (TORG1323)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 14 Dec 2017
At a glance
- Drugs Bevacizumab (Primary) ; Docetaxel; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 11 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 03 Mar 2014 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.
- 16 Jan 2014 New trial record